ALNY News and Press, Alnylam Pharmaceuticals Inc. From 10/16/23

2023-10-16 18:39:22 ET Summary Arbutus Biopharma Corporation is a small biopharma company focused on developing therapeutics for chronic Hepatitis B virus infection. The company recently dropped two drug candidates in development to increase focus on advancing its primary asset wi...

2023-10-13 18:11:38 ET Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA o...

NEW YORK, NY / ACCESSWIRE / October 11, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ:ALNY). Investors who purchased Alnylam securities are encouraged to obtain additio...

2023-10-11 12:26:19 ET More on Alnylam Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatili...

2023-10-10 18:08:45 ET Summary Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Amvuttra has always been the bigger opportunity in ATTR...

2023-10-10 14:48:17 ET Summary Alnylam's stock declined after the FDA issued a complete response letter citing inadequate evidence to support the efficacy of Onpattro in treating ATTR amyloidosis patients with cardiomyopathy. This is a minor setback because the HELIOS-B trial of A...

2023-10-09 13:48:11 ET The FDA's decision to reject a label expansion for Alnylam’s ( NASDAQ: ALNY ) amyloidosis therapy patisiran on Monday pressured shares of Arbutus Biopharma ( NASDAQ: ABUS ), which has out-licensed the product to the RNAi therapeutics company. ...

2023-10-09 07:49:29 ET More on Alnylam Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility Alnylam: Unlimited Promise Or Unlimited Losses? Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Ionis, A...

– FDA Cites Insufficient Evidence of Clinical Meaningfulness – – No Clinical Safety, Study Conduct, Drug Quality or Manufacturing Issues Identified – – CRL Does Not Pertain to, nor Impact Commercial Availability of, ONPATTRO ® (patisiran...

2023-10-08 06:29:00 ET Growth-oriented investors looking for stocks that can heat up their portfolios before the end of 2023 want to turn their attention to the healthcare sector. Upcoming binary events could soon send these two biotech stocks rocketing higher. The U.S. Food and Drug Ad...